Insmed Overview
- Year Founded
-
1988
- Status
-
Public
- Employees
-
912
- Stock Symbol
-
INSM
- Investments
-
6
- Share Price
-
$73.23
- (As of Monday Closing)
Insmed General Information
Description
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
Contact Information
Website
www.insmed.comCorporate Office
- 700 US Highway 202/206
- Bridgewater, NJ 08807
- United States
Corporate Office
- 700 US Highway 202/206
- Bridgewater, NJ 08807
- United States
Insmed Stock Performance
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $73.23 | $74.66 | $21.92 - $80.53 | $12.6B | 172M | 2.32M | -$5.41 |
Insmed Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 11,543,959 | 4,844,741 | 3,023,307 | 2,979,107 |
| Revenue | 328,605 | 305,208 | 245,358 | 188,461 |
| EBITDA | (712,543) | (662,038) | (447,296) | (383,629) |
| Net Income | (802,694) | (749,567) | (481,534) | (434,654) |
| Total Assets | 1,810,118 | 1,329,837 | 1,656,435 | 1,243,508 |
| Total Debt | 1,217,386 | 1,203,994 | 1,177,865 | 612,268 |
Insmed Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Insmed Comparisons
Industry
Financing
Details
000000
000000
Insmed Competitors (84)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Ardelyx | Formerly VC-backed | Fremont, CA | 000 | 00000 | 000000000 00 | 00000 |
| Blueprint Medicines | Formerly VC-backed | Cambridge, MA | 000 | 00.000 | 000000000000 | 00.000 |
| Arrowhead Pharmaceuticals | Corporation | Pasadena, CA | 000 | 00.000 | 000000000000 | 00.000 |
| Rallybio | Formerly VC-backed | New Haven, CT | 00 | 00000 | 00000000 | 00000 |
| Aura Biosciences | Formerly VC-backed | Cambridge, MA | 00 | 00000 | 00000000 | 00000 |
Insmed Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Insmed Patents
Insmed Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023221393-A1 | Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa | Pending | 16-Feb-2022 | 000000000 | |
| AU-2022376535-A1 | Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating chronic rhinosinusitis | Pending | 29-Oct-2021 | 0000000000 | |
| EP-4423071-A1 | Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating chronic rhinosinusitis | Pending | 29-Oct-2021 | 0000000000 | |
| CA-3236069-A1 | Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating chronic rhinosinusitis | Pending | 29-Oct-2021 | 0000000000 | |
| CA-3224482-A1 | Adeno-associated virus particles and methods of use thereof | Pending | 05-Aug-2021 | A61K48/0008 |
Insmed Executive Team (32)
| Name | Title | Board Seat |
|---|---|---|
| William Lewis JD | Chief Executive Officer & Chairman | |
| Sara Bonstein | Chief Financial Officer, Finance | |
| Roger Adsett | Chief Operating Officer, Operations | |
| Walter Perkins Ph.D | Chief Technology Officer | |
| Drayton Wise | Executive |
Insmed Board Members (14)
| Name | Representing | Role | Since |
|---|---|---|---|
| Alfred Altomari | Self | Board Member | 000 0000 |
| Carol Schafer | Self | Board Member | 000 0000 |
| Clarissa Desjardins Ph.D | Self | Board Member | 000 0000 |
| David Brennan | Self | Board Member | 000 0000 |
| David McGirr | Self | Board Member | 000 0000 |
Insmed Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Insmed Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Insmed Acquisitions (6)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Insmed Innovation | 30-Jun-2023 | 0000000000 | 00000 | Drug Discovery | |
| Vertuis Bio | 06-Jan-2023 | 0000000000 | 000.00 | Drug Discovery | |
| AlgaeneX | 04-Aug-2021 | 0000000000 | 000.00 | Drug Discovery | |
| Motus Biosciences | 04-Aug-2021 | 0000000000 | 00000 | Biotechnology | |
| Transave | 01-Dec-2010 | Merger/Acquisition | 0000 | Drug Delivery |
Insmed Subsidiaries (1)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| AlgaeneX | Drug Discovery | San Diego, CA | 0000 |
Insmed ESG
Risk Overview
Risk Rating
Updated March, 01, 2024
25.69 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 16,009
Rank
Percentile
Pharmaceuticals
Industry
00 of 909
Rank
Percentile
Biotechnology
Subindustry
00 of 404
Rank
Percentile
Insmed FAQs
-
When was Insmed founded?
Insmed was founded in 1988.
-
Who is the CEO of Insmed?
William Lewis JD is the CEO of Insmed.
-
Where is Insmed headquartered?
Insmed is headquartered in Bridgewater, NJ.
-
What is the size of Insmed?
Insmed has 912 total employees.
-
What industry is Insmed in?
Insmed’s primary industry is Biotechnology.
-
Is Insmed a private or public company?
Insmed is a Public company.
-
What is Insmed’s stock symbol?
The ticker symbol for Insmed is INSM.
-
What is the current stock price of Insmed?
As of 16-Sep-2024 the stock price of Insmed is $73.23.
-
What is the current market cap of Insmed?
The current market capitalization of Insmed is $12.6B.
-
What is Insmed’s current revenue?
The trailing twelve month revenue for Insmed is $329M.
-
Who are Insmed’s competitors?
Ardelyx, Blueprint Medicines, Arrowhead Pharmaceuticals, Rallybio, and Aura Biosciences are some of the 84 competitors of Insmed.
-
What is Insmed’s annual earnings per share (EPS)?
Insmed’s EPS for 12 months was -$5.41.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
